Related Experiment Videos
Pneumocystis carinii pneumonia: pitfalls of prophylaxis
R J Massie1, P J Cooper, P P Van Asperen
1Respiratory Medicine, Royal Alexandria Hospital for Children, Sydney, Australia. massiej@cryptic.rch.unimelb.edu.au
Abstract:
Pneumocystis carinii pneumonia (PCP) occurs commonly in immunocompromised patients. Sulfamethoxazole-trimethoprim (SMX-TMP) is effective prophylaxis, although PCP may still occur despite apparently adequate use. We report three cases of PCP which highlight some of the pitfalls of prophylaxis.
Insights
Despite effective prophylaxis with Sulfamethoxazole-trimethoprim (SMX-TMP), Pneumocystis carinii pneumonia (PCP) can still occur in immunocompromised patients. This report details three cases that reveal potential issues with PCP prophylaxis.
Area of Science:
- Infectious Diseases
- Immunology
- Pulmonology
Background:
- Pneumocystis carinii pneumonia (PCP) is a significant opportunistic infection in immunocompromised individuals.
- Sulfamethoxazole-trimethoprim (SMX-TMP) is a standard prophylactic agent against PCP.
- Despite prophylaxis, PCP can still develop, necessitating an understanding of potential failures.
Observation:
- This report presents three clinical cases of PCP.
- These cases occurred in patients receiving SMX-TMP for prophylaxis.
- The cases illustrate specific circumstances where prophylaxis may be less effective.
Findings:
- Prophylaxis with SMX-TMP may not always prevent PCP.
- Factors such as adherence, drug interactions, or host immune status can influence treatment efficacy.
- Understanding these nuances is crucial for optimizing PCP prevention strategies.
Implications:
- Clinical vigilance is required even when patients are on PCP prophylaxis.
- Further research may be needed to identify optimal prophylactic regimens or patient subgroups.
- These findings underscore the importance of considering alternative or adjunctive strategies for PCP prevention in high-risk populations.